EGFR and neoplasm: We and others have noted that EGFR degradation upon gemcitabine, cisplatin or radiation increases tumor cell-specific cytotoxicity beyond that of EGFR inhibition alone [12-19], and TKI-resistant cells are responsive to therapies that induce EGFR degradation [19-22].